NICE OKs Remicade, Enbrel and Humira for psoriatic arthritis
This article was originally published in Scrip
NICE, the health technology appraisal institute for England and Wales, says that physicians can now prescribe Abbott's Humira (adalimumab), Wyeth's Enbrel (etanercept) and Merck & Co's Remicade (infliximab) for some NHS patients with psoriatic arthritis. The institute issued final guidance along these lines this week.
You may also be interested in...
The German pricing and reimbursement system has been successful in recognizing the value and uniqueness of orphan drugs.
Canada has announced new restrictions on exports to help mitigate the impact of measures in the US to lower medicine prices there.
In the wake of the COVID-19 pandemic and the ensuing economic fallout, pharmaceutical companies could face a range of measures designed to cut government spending on medicines. From relaxing intellectual property rights to delaying reimbursement, In Vivo examines what might be in store for industry.